AI MARKET SCANNING

Alvotech

📅 Next Catalyst: Nov 11, 2026 (🌙 Close) 🏛️ NASDAQ 📁 Healthcare 🏭 Drug Manufacturers – Specialty & Generic
AVG HISTORICAL GAP -1.08%
MAX GAP RECORD -7.28%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $ALVO
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 11, 2026 Earnings Release 2026-11-11 (AFTER CLOSE (21:00)) 🔮 UPCOMING 🔒
Aug 19, 2026 Earnings Release 2026-08-19 (AFTER CLOSE)
-2.51%
May 06, 2026 Earnings Release 2026-05-06 (AFTER CLOSE)
-7.28%
Mar 18, 2026 Earnings Release 2026-03-18 (BEFORE OPEN)
-0.79%
Nov 12, 2025 Earnings Release 2025-11-12 (AFTER CLOSE)
-6.96%
Aug 13, 2025 Earnings Release 2025-08-13 (AFTER CLOSE)
-1.23%
Mar 26, 2025 Earnings Release 2025-03-26 (AFTER CLOSE)
-0.69%
Nov 13, 2024 Earnings Release 2024-11-13 (AFTER CLOSE)
+5.36%

VOLATILITY & GAP BIAS

AVG GAP MOVE 2.7%
Bullish Gaps (4)
Bearish Gaps (5)
Neutral / Flat (2)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $ALVO

EXECUTIONS1 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
2026-10-30 🔒 PRO RADAR ••• x• $•••.•• → $•••.•• 2488m +0.36%
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗